The University of Southampton
University of Southampton Institutional Repository

DNA vaccines: precision tools for activating effective immunity against cancer

DNA vaccines: precision tools for activating effective immunity against cancer
DNA vaccines: precision tools for activating effective immunity against cancer
DNA vaccination has suddenly become a favoured strategy for inducing immunity. The molecular precision offered by gene-based vaccines, together with the facility to include additional genes to direct and amplify immunity, has always been attractive. However, the apparent failure to translate operational success in preclinical models to the clinic, for reasons that are now rather obvious, reduced initial enthusiasm. Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer
plasmid dna, immunity, phase-i, cancer, gene, protective immunity, minor histocompatibility antigens, development, genes, electroporation in-vivo, tumor-antigen, treatment, models, vaccine, b surface-antigen, time, dna, model, refractory prostate-cancer, cd8(+) t-cells, dendritic cells
1474-175X
108-120
Rice, J.
d58d4fcd-8dc0-4599-bf96-62323d579227
Ottensmeier, C.H.
42b8a398-baac-4843-a3d6-056225675797
Stevenson, F.K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Rice, J.
d58d4fcd-8dc0-4599-bf96-62323d579227
Ottensmeier, C.H.
42b8a398-baac-4843-a3d6-056225675797
Stevenson, F.K.
ba803747-c0ac-409f-a9c2-b61fde009f8c

Rice, J., Ottensmeier, C.H. and Stevenson, F.K. (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer, 8 (2), 108-120. (doi:10.1038/nrc2326).

Record type: Article

Abstract

DNA vaccination has suddenly become a favoured strategy for inducing immunity. The molecular precision offered by gene-based vaccines, together with the facility to include additional genes to direct and amplify immunity, has always been attractive. However, the apparent failure to translate operational success in preclinical models to the clinic, for reasons that are now rather obvious, reduced initial enthusiasm. Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer

This record has no associated files available for download.

More information

Published date: 2008
Keywords: plasmid dna, immunity, phase-i, cancer, gene, protective immunity, minor histocompatibility antigens, development, genes, electroporation in-vivo, tumor-antigen, treatment, models, vaccine, b surface-antigen, time, dna, model, refractory prostate-cancer, cd8(+) t-cells, dendritic cells

Identifiers

Local EPrints ID: 62896
URI: http://eprints.soton.ac.uk/id/eprint/62896
ISSN: 1474-175X
PURE UUID: 876254f0-5a27-477a-8b85-03afe7b19b9e
ORCID for F.K. Stevenson: ORCID iD orcid.org/0000-0002-0933-5021

Catalogue record

Date deposited: 12 Sep 2008
Last modified: 16 Mar 2024 02:54

Export record

Altmetrics

Contributors

Author: J. Rice
Author: F.K. Stevenson ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×